| <img alt="" height="1" width="1" />Endo acquires PenWest Pharma. ILNS awarded patent. Curis drug needs more analysisBioMedReports (subscription) (blog)Non-constipation irritable bowel syndrome (Non-C IBS) encompasses two of the most common IBS subtypes: patients with diarrhea-predominant symptoms (IBS-D) ...<nobr>and more »</nobr> |
Google- Endo acquires PenWest Pharma. ILNS awarded patent. Curis drug needs more analysis - BioMedReports (subscription) (blog)
Join the discussion
